CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

December 28, 2017

Primary Completion Date

August 31, 2026

Study Completion Date

October 31, 2026

Conditions
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System LymphomaRefractory Primary Central Nervous System Lymphoma
Interventions
DRUG

Emavusertib

Emavusertib will be provided as a tablet dosage form to be taken BID.

DRUG

Ibrutinib

Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.

Trial Locations (43)

10029

RECRUITING

Mt Sinai, New York

10032

RECRUITING

Columbia University Irving Medical Center, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

15232

RECRUITING

UPMC Hilman Cancer Center, Pittsburgh

19104

COMPLETED

Hospital of the University of Pennsylvania, Philadelphia

27710

RECRUITING

Duke University Medical Center, Duke Cancer Center, Durham

32224

RECRUITING

Mayo Clinic, Jacksonville

37920

ACTIVE_NOT_RECRUITING

University of Tennessee Medical Center, Knoxville

44195

RECRUITING

Cleveland Clinic, Cleveland

55905

RECRUITING

Mayo Clinic, Rochester

60611

RECRUITING

Northwestern Memorial Hospital, Chicago

68198

RECRUITING

Fred and Pamela Buffett Cancer Center, Omaha

75235

RECRUITING

UT Southwestern Medical Center, Dallas

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

84112

RECRUITING

Huntsman Cancer Institute, University of Utah, Salt Lake City

85013

RECRUITING

St. Joseph's Hospital and Medical Center, Phoenix

85054

RECRUITING

Mayo Clinic, Phoenix

90404

RECRUITING

Providence St. John's Health Center, Santa Monica

WITHDRAWN

UCLA Department of Medicine - Hematology/Oncology, Santa Monica

91010

RECRUITING

City of Hope, Duarte

97225

RECRUITING

Providence Neurological Specialties West, Portland

98104

COMPLETED

Swedish Cancer Institute, Seattle

98195

RECRUITING

University of Washington Medical Center, Seattle

06510

RECRUITING

Smilow Cancer Hospital at Yale-New Haven, New Haven

02215

RECRUITING

Dana Farber Cancer Institute, Boston

07601

ACTIVE_NOT_RECRUITING

Hackensack University Medical Center, Hackensack

Unknown

RECRUITING

Všeobecná fakultní nemocnice v Praze, Prague

RECRUITING

Institut Bergonie, Bordeaux

RECRUITING

Hopital de la Timone, Marseille

RECRUITING

Hospital Pitie Salpetriere, Paris

RECRUITING

Institut Curie Hospital, Paris

RECRUITING

Hematology Department Soroka UMC / Heanatology Department, Beersheba

RECRUITING

Hadassah Medical Center / Ein-Carem, Jerusalem

RECRUITING

Università di Torino Croce e Carle, Cuneo

RECRUITING

SODc Ematologia Azienda Ospedaliera Universitaria Careggi, Florence

RECRUITING

IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola

RECRUITING

IRCCS San Raffaele Scientific Institute, Milan

RECRUITING

Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz, Gdansk

WITHDRAWN

Oddzial Kliniczny Hematologii, Krakow

RECRUITING

NarodowyInstytutu Onkologii im. Marii Sklodowskiej-Curie-Panstwowy Instytutu Badawczy, Warsaw

RECRUITING

MD Anderson Cancer Center Madrid, Madrid

RECRUITING

Hospital Universitario Virgen del Rocio, Seville

All Listed Sponsors
lead

Curis, Inc.

INDUSTRY